Insider information pursuant to Article 17 of the Market Abuse Regulation [MAR] 

H&R GmbH & Co. KGaA: Preliminary Figures for nine months of 2024

• Sales revenues exceed EUR 1.0 billion once again
• EBITDA at previous year's level of EUR 65.9 million (first nine months of 2023: EUR 66.6 million)
• Earnings stabilization in the third quarter of 2024

Salzbergen, Germany, 18. October 2024. H&R GmbH & Co. KGaA (short: H&R KGaA; ISIN DE000A2E4T77) recorded a recovery trend of stable sales and earnings development at the end of the third quarter of 2024. According to preliminary calculations, the consolidated operating result (EBITDA*) amounted to EUR 24.8 million in the third quarter (Q3-2023: EUR 27.2 million). Overall, the third quarter of the 2024 financial year showed the strongest momentum to date. The other results in detail: EBIT closed at EUR 9.0 million after last year's EUR 13.0 million. Earnings before taxes (EBT) amounted to EUR 5.8 million in the third quarter of 2024 (Q3-2023: EUR 9.6 million), while the company closed with EUR 3.5 million in net income attributable to shareholders (Q3-2023: EUR 7.6 million). Revenue in the third quarter of the current financial year increased slightly to EUR 338.1 million (Q3-2023: EUR 337.2 million).

Looking at the entire nine-month period of 2024, the Group achieved stable preliminary EBITDA of EUR 65.9 million (first nine months of 2023: EUR 66.6 million) and slightly weaker sales revenues of EUR 1,013.6 million (first nine months of 2023: EUR 1,036.8 million) as a result of the previous quarters. Depreciation and amortization increased by around 6.5% compared to the previous year, resulting in EBIT of EUR 20.6 million (first nine months of 2023: EUR 24.1 million). There was a similar trend in earnings before taxes (EBT), which amounted to EUR 11.1 million (first nine months of 2023: EUR 15.2 million). Consolidated net income attributable to shareholders closed at EUR 6.3 million (first nine months of 2023: EUR 11.3 million). H&R KGaA thus generated earnings per share of EUR 0.17; at EUR 0.09, the third quarter of 2024 (first nine months of 2023: EUR 0.30; Q3-2023: EUR 0.20) made the largest contribution during the year.

Reversing the trend of previous quarters, the ChemPharm REFINING segment made the main contribution to earnings for the first time this year. With EBITDA of EUR 15.3 million in the third quarter of 2024 (Q3-2023: EUR 20.9 million), it nevertheless performed weaker than in the same quarter of the previous year. At EUR 35.8 million (first nine months of 2023: EUR 43.2 million), the segment performance for the first nine months of the year was at a reduced but nevertheless stable level as a result of the recent improvement in performance. Sales in the segment amounted to EUR 621.8 million for the nine-month period (first nine months of 2023: EUR 634.1 million).

At EUR 9.7 million in the third quarter and EUR 30.8 million in the nine-month period, our international activities in the ChemPharm SALES segment recorded a strong overall recovery in operating results (Q3-2023: EUR 8.1 million; first nine months of 2023: EUR 21.9 million). At EUR 370.2 million, revenue in the nine-month period and EUR 126.6 million in the quarter was down on the previous year (first nine months of 2023: EUR 380.2 million; Q3-2023: EUR 129.0 million).

The PLASTICS segment generated a reduced operating result of EUR 1.7 million for the nine-month period compared to the previous year (first nine months of 2023: EUR 3.0 million), with the third quarter of 2024 in particular making a positive contribution of EUR 0.5 million (Q3 2023: EUR 0.0 million). At EUR 36.3 million and EUR 12.1 million respectively, sales developed inconsistently compared to the previous year's figures (first nine months of 2023: EUR 38.3 million; Q3 2023: EUR 12.0 million), primarily as a result of the ongoing tense situation in the automotive industry.

At EUR 53.8 million in the first nine months of 2024 (first nine months of 2023: EUR 73.0 million), operating cash flow was weaker than in the same period of the previous year. Based on a lower consolidated result, it was burdened during the year primarily by increased interest and income tax expenses. In total, however, it amounted to a significantly recovered EUR 48.3 million in the third quarter of 2024 (Q3-2023: EUR 16.2 million), while free cash flow amounted to EUR 36.2 million (Q3-2023: EUR 8.1 million). As at the reporting date for the nine-month period, free cash flow amounted to EUR 17.6 million after EUR 32.7 million in the previous year.

Compared to December 31, 2023, total assets increased from EUR 903.2 million to EUR 943.6 million. Equity increased from EUR 457.6 million to EUR 464.5 million in the same period. As of September 30, 2024, the company's equity ratio was 49.2% (December 31, 2023: 50.7%).

Overall, the company is therefore on track to achieve a similar result to the previous year and should therefore reach the range that has remained unchanged since the beginning of the year. Details as to whether and to what extent this will be the case will be provided as the year progresses.

The final financial figures and further information on business performance to date in 2024 will be published as planned in the quarterly statement on November 14, 2024.

Contact:
H&R GmbH & Co. KGaA, Head of Investor Relations / Communication, Ties Kaiser
Neuenkirchener Straße 8, 48499 Salzbergen
Phone.: +49 40 43218-321, Fax: +49 40 43218-390
Mail: ties.kaiser@hur.com
www.hur.com

H&R GmbH & Co. KGaA:
Listed in the Prime Standard of the Frankfurt Stock Exchange, H&R GmbH & Co. KGaA is a specialty chemicals company active in the development and manufacture of chemical-pharmaceutical specialty products based on fossil, bio-based, synthesized and recycled hydrocarbons and in the production of precision plastic parts.

Forward-looking statements and forecasts:
This insider information pursuant to Article 17 of the Market Abuse Regulation [MAR] contains forward-looking statements. The statements are based on the current estimates and forecasts by the Management Team and the information available to it at this time. These forward-looking statements do not provide any warranty for the future developments and results contained therein. The future developments and results are dependent on a number of factors; they entail various risks and contingencies and are based on assumptions which could prove to be incorrect. We do not assume any responsibility for updating the forward-looking statements contained in this insider information pursuant to Article 17 of the MAR.